The American Association for Cancer Research (AACR) Annual Meeting 2026, one of the most influential academic events in global oncology, will be held from April 17 to 22, 2026, in San Diego, USA. At this year’s AACR conference, Henlius will showcase seven early-stage innovative assets with first-in-class (FIC) or best-in-class (BIC) potential. These include HLX43 (PD-L1 ADC), HLX316 (B7-H3×sialidase fusion protein), HLX3902 (STEAP1×CD3×CD28 trispecific T-cell engager), as well as multiple novel ADC candidates developed based on proprietary platform Hanjugator™, including the EGFR×cMET bispecific ADC HLX48, HER2 biparatopic ADC HLX49, ADAM9 ADC HLX402, and ALPP/ALPPL2 ADC HLX85. Together, these innovative assets span cutting-edge modalities including ADCs, TCE, and novel glyco-immunomodulatory fusion protein, highlighting Henlius’ differentiated, multi-platform-driven innovation matrix.
________________________________________
Seven Innovative Assets with FIC/BIC Potential
HLX43 (PD-L1 ADC)
•Title: Preclinical studies reveal that protease-mediated payload release and immuno-oncology/immunomodulatory effects contribute to the antitumor activity of HLX43
•Session Title: Mechanisms of Anticancer Drug Action
•Format: Poster Session
•Abstract Number: 5704
•Date and Time: April 21, 2026, 2:00 PM-5:00 PM ET
•: Poster Section 12, Board #20
________________________________________
HLX316 (B7-H3 × Sialidase Fusion Protein)
•Title: Human sialidase-armed anti-B7-H3 antibody that enhances innate and adaptive antitumor immune responses
•Session Title: Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy
•Format: Poster Session
•Abstract Number: 7158
•Date and Time: April 22, 2026, 9:00 AM-12:00 PM ET
•: Poster Section 15, Board #15
________________________________________
HLX3902 (STEAP1 × CD3 × CD28 Tri-specific TCE)
•Title: A novel anti-CD3×CD28×STEAP1 tri-specific T-cell engager with enhanced and durable antitumor responses in prostate cancer
•Session Title: Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 2
•Format: Poster Session
•Abstract Number: 5397
•Date and Time: April 21, 2026, 9:00 AM-12:00 PM ET
•: Poster Section 48, Board #10
________________________________________
Hanjugator™ Platform & HLX48（EGFR×cMET ADC）
•Title: Hanjugator camptothecin platform: effective, low-toxicity design maximizing antibody functionality and enabling a potential best-in-class EGFR/cMet bispecific ADC
•Session Title: Tumor Microenvironment, Multispecifics, and Immunomodulation
•Format: Poster Session
•Abstract Number: 5856
•Date and Time: April 21, 2026, 2:00 PM-5:00 PM ET
•: Poster Section 17, Board #25
________________________________________
HLX49 (HER2xHER2 Biparatopic ADC)
•Title: A best-in-class HER2xHER2 biparatopic antibody-drug conjugate with an efficacious, low-toxicity design that maximizes antibody functionality
•Session Title: Antibody Technologies and Platforms 2
•Format: Poster Session
•Abstract Number: 4395
•Date and Time: April 21, 2026, 9:00 AM-12:00 PM ET
•: Poster Section 11, Board #3
________________________________________
HLX402 (ADAM9 ADC)
•Title: Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9
•Session Title: Antibody Technologies and Platforms 2
•Format: Poster Session
•Abstract Number: 4418
•Date and Time: April 21, 2026, 9:00 AM-12:00 PM ET
•: Poster Section 11, Board #26
________________________________________
HLX85 (ALPP/ALPPL2 ADC)
•Title: Development of a first-in-class camptothecin-based antibody-drug conjugate targeting ALPP/ALPPL2 with potent antitumor activity and excellent tolerability
•Session Title: Antibody Technologies and Platforms 2
•Format: Poster Session
•Abstract Number: 4419
•Date and Time: April 21, 2026, 9:00 AM-12:00 PM ET
•: Poster Section 11, Board #27
________________________________________
Integrated Platforms Driving Sustainable Innovation
The findings to be presented at AACR 2026 underscore Henlius’ expanding innovation footprint across ADCs, TCEs, and immuno-oncology(IO).
Henlius has established an integrated R&D system spanning target identification and validation, candidate design and optimization, and systematic preclinical development. This system is supported by a multi-dimensional technology platform framework, including a PD-(L)1-centred immune checkpoint inhibitor platform, immune cell engager platforms such as multi-specific T-cell engagers (TCEs), the Hanjugator™ ADC platform, and the AI-driven one-stop early discovery platform HAI Club. Together, these platforms support the efficient advancement of individual programs and contribute to the development of a differentiated and globally competitive pipeline. By enabling the translation of scientific discoveries into clinical-stage candidates, Henlius continues to advance its early-stage innovation capabilities. Looking ahead, the company expects to submit more than 40 investigational new drug (IND) applications over the next five years.
